Adicet Bio Inc Stock Price, News & Analysis

Adicet Bio (Nasdaq: ACET) has reached a significant milestone in its Phase 1 clinical trial of ADI-001 for autoimmune diseases, announcing the dosing of the first systemic sclerosis (SSc) patient in the trial's second cohort. The study is actively enrolling patients across three conditions: lupus nephritis (LN), systemic lupus erythematosus (SLE), and systemic sclerosis (SSc).

The company's Chief Medical Officer, Dr. Julie Maltzman, highlighted the critical unmet need for effective treatments in autoimmune diseases and expressed optimism about ADI-001's potential therapeutic benefits. Preliminary clinical data from this Phase 1 trial is expected in the second half of 2025.

Adicet Bio (NASDAQ: ACET), a clinical stage biotechnology company focused on developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's President and CEO, Chen Schor, will engage in a fireside chat on June 4, 2025, at 4:20 p.m. ET in New York. The presentation will be accessible via live audio webcast on Adicet Bio's website, with a replay available for 30 days afterward.

Adicet Bio (NASDAQ: ACET) reported Q1 2025 financial results and provided key updates on its clinical programs. The company is advancing two key programs with data readouts expected in 2H/2025: ADI-001 for autoimmune diseases and ADI-270 for clear cell renal cell carcinoma (ccRCC). The Phase 1 trial for ADI-001 has expanded enrollment to include lupus nephritis and systemic lupus erythematosus patients, with FDA granting Fast Track Designations. Financial highlights show R&D expenses of $22.8M (down from $23.9M in Q1 2024), with a net loss of $28.2M ($0.31 per share). The company maintains a strong cash position of $150.4M, expected to fund operations into 2H/2026.

Adicet Bio has announced new inducement grants under Nasdaq Listing Rule 5635(c)(4). The clinical-stage biotech company, focused on developing allogeneic gamma delta T cell therapies, granted stock options to three new employees hired in April 2025.

The key details of the grants include:

• Total shares: 206,800 of common stock
• Exercise price: $0.66 per share
• Vesting schedule: 25% after one year, remaining 75% over 36 monthly installments
• Full vesting period: 4 years

These awards were granted through Adicet's 2022 Inducement Plan, which was amended in January 2023. The compensation committee approved these grants as material inducement for new employees, complying with Nasdaq regulations.

Adicet Bio (Nasdaq: ACET), a clinical stage biotech company focused on developing allogeneic gamma delta T cell therapies, has announced its upcoming participation in the 2025 Citizens JMP Life Sciences Conference.

The company's President and CEO, Chen Schor, will engage in a fireside chat at the conference, which is scheduled for May 7-8, 2025 in New York. The presentation is set for Wednesday, May 7, 2025, at 1:30 p.m. ET.

Investors and interested parties can access the live audio webcast through the Investors section of Adicet Bio's website at www.adicetbio.com. A replay of the presentation will remain available on the website for 30 days following the event.

Adicet Bio (Nasdaq: ACET), a clinical stage biotechnology company focused on allogeneic gamma delta T cell therapies, has appointed Michael Grissinger to its Board of Directors. Grissinger brings over 40 years of pharmaceutical business development and strategic transaction experience, including more than two decades at Johnson & Johnson where he served as Vice President and Head of Worldwide Pharmaceutical Licensing and Corporate Development.

During his tenure at Johnson & Johnson, Grissinger led the Immunology Therapeutic Area Business Development and Licensing Group and was a member of the Immunology R&D/Commercial leadership team. Prior to J&J, he spent 12 years at Ciba-Geigy in finance, marketing, and business development roles. He currently serves on the board of Aprea Therapeutics and three private biotech companies.

Adicet Bio (Nasdaq: ACET) has granted inducement awards to two new employees hired in March 2025. The awards consist of non-qualified stock options to purchase 38,600 shares of Adicet's common stock at an exercise price of $0.76 per share, matching the closing price on March 31, 2025.

The vesting schedule includes 25% of shares vesting after one year, with the remaining 75% vesting in 36 monthly installments. Full vesting occurs on the fourth anniversary, contingent on continued employment. These awards were granted through Adicet's 2022 Inducement Plan, approved by the compensation committee as material inducement for employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Adicet Bio (Nasdaq: ACET), a biotechnology company focused on developing allogeneic gamma delta T cell therapies, has announced its participation in the upcoming 2025 Canaccord Genuity Horizons in Oncology Virtual Conference.

The company's President and CEO, Chen Schor, will be featured in a panel discussion titled 'CAR T Approaches in the Autoimmune Space' scheduled for Monday, April 7, 2025, at 3:00 p.m. ET. This virtual conference appearance highlights Adicet's ongoing work in both autoimmune diseases and cancer treatments.